Drug Delivery System Market Size, Share, Opportunities, And Trends By Delivery System (Intra Uterine Implants, Pro-drug Implants, Polymeric Drug Delivery, Targeted Drug Delivery), By Route of Administration (Oral, Injectable, Inhalation, Transdermal, Ocular, Nasal, Topical), By Application (Infectious Disease, Oncology, Ophthalmology, Urology, Diabetes, CNS, Others), And By Geography - Forecasts From 2024 To 2029

The drug delivery system market is anticipated to grow significantly over the forecast period.

The market for drug delivery systems (DDS) is a dynamic industry that includes a range of technologies and approaches for efficiently administering medicinal drugs. It seeks to reduce side effects, increase patient compliance, and improve medication efficacy. The development of formulation science, nanotechnology, and biotechnology—which enable targeted distribution, prolonged release, and enhanced bioavailability—are important motivators. The market covers a wide range of applications, with an increasing emphasis on personalized medicine. These applications include diabetes, cardiovascular disorders, and cancer.

Additionally, new developments in delivery platforms, including liposomes, nanoparticles, and implantable devices, have been sparked by the popularity of gene treatments and biologics. Investments in R&D and regulatory backing fuel industry expansion even more. Regulatory obstacles and intricate production procedures are still problems, though. In general, the worldwide market for drug delivery systems is still growing due to technological advancements and the growing need for treatment options that are more effective and pleasant for patients.

Market Drivers 

•  Technological advancements in the drug delivery system market are anticipated to boost the market.

The market for drug delivery systems is driven by technological advancements that make it possible to give therapeutic substances more accurately and effectively. The production of nanoparticles for targeted medicine administration is made easier by nanotechnology, which also helps to minimize side effects and increase efficacy. Innovations in biotechnology, including recombinant DNA technology, make it possible to produce biologics, which need specific delivery methods. Innovations in formulation science enable the creation of innovative medication formulations with enhanced sustained release and bioavailability.

Furthermore, new technologies such as 3D printing and microfluidics provide possibilities for customized medication and the production of drug delivery devices on demand. Drug delivery systems are continuously improved by these technical advancements, leading to safer and more effective therapies.

In October 2023, Medtronic plc showcased cross-continent real-world statistics showing that independent of global location, persons with diabetes can meet or surpass internationally approved targets when using the MiniMedTM 780G system. Because there are significant differences in the representation of different ethnic, cultural, and regional groups in clinical and real-world studies on the use and results of technology in type 1 diabetes (T1D), one of the obstacles to the adoption and reimbursement of automated insulin delivery (AID) in developing and middle-income countries has been the lack of data supporting AID performance and cost-effectiveness in these regions. The positive effects shown by this research highlight the need to give automated insulin delivery systems to anyone who wants improved results, particularly in underserved communities.

• The shift of patients towards advanced drug delivery systems is expected to drive the drug delivery system market.

Patients are increasingly using sophisticated drug delivery devices for a variety of reasons. More and more patients are looking for therapies with higher convenience, fewer side effects, and better efficacy. These demands are met by advanced drug delivery systems, which offer alternatives for personalized treatment, prolonged release, and targeted distribution. Furthermore, the need for long-term medication management due to the rising prevalence of chronic diseases is creating a demand for novel delivery systems that increase patient compliance.

Additionally, the growing accessibility of gene therapies and biologics necessitates the development of advanced delivery systems that can safely and efficiently give these intricate medicines. All things considered, the need for more efficient and patient-centered healthcare solutions is reflected in patients' choice of sophisticated medication delivery systems.

According to NCBI in 2023, recent drug delivery systems are acknowledged as the most recent advancements and creative comprehension of the pharmacokinetic and pharmacodynamic behaviour of pharmaceuticals in the building of an ideal drug administration system. These DDS can carry material to the site of action and maintain drug concentrations in the therapeutic range for extended periods of time since they are transporters. Adoption of the delivery method is closely related to the innovation's commercial and therapeutic success.

• Increasing chronic diseases is anticipated to boost the drug delivery system market

Drug delivery methods are significantly impacted by the rise of chronic illnesses. Because long-term medication management is frequently necessary for chronic disorders like diabetes, cardiovascular disease, and cancer, there is a growing need for efficient drug delivery systems. To sustain therapeutic levels over prolonged periods, many disorders may require frequent dosing, precise distribution to certain target areas, and sustained release formulations.

Furthermore, the intricacy of therapies, such as gene and biological therapies, emphasizes how crucial it is to have sophisticated delivery systems that can safely and effectively administer these medications. To fulfill changing healthcare needs, the rise in chronic diseases consequently stimulates the development and deployment of novel drug delivery systems.

According to WHO, in 2023, Noncommunicable diseases (NCDs) account for 41 million annual deaths worldwide, or 74% of all fatalities.17 million individuals die from NCDs before they become 70 years old every year; low- and middle-income nations account for 86% of these premature fatalities.77% of NCD-related deaths occur in low- and middle-income nations. The majority of NCD deaths—17.9 million annually—are caused by cardiovascular illnesses, which are followed by death by cancer (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including deaths from renal disease induced by diabetes).

Asia Pacific region is expected to grow significantly

The market for medication delivery systems is expanding significantly in the Asia-Pacific area for several reasons. The desire for better treatment alternatives is driven by two factors: increased healthcare expenditure and rapid urbanization. Additionally, the region has a sizable patient population, especially in China and India, which presents a sizable market opportunity. The adoption of novel medication delivery methods is fueled by the rising prevalence of chronic diseases and the developing understanding of personalized treatment.

Supportive government programs, infrastructure expenditures in the healthcare sector, and partnerships with international pharmaceutical firms further aid in the DDS market growth in the Asia-Pacific area. For instance, in March 2023, the government of India launched the Heal in India initiative to encourage medical tourism there. The Center for Development of Advanced Computing (CDAC) and the Services Export Promotion Council (SEPC) have been collaborating with the Ministries of Health and Family Welfare and Ayush in this effort to establish a "One Step" Heal in India portal for the promotion of Medical Value Travel.

Market Restraints

• Rules and regulations and recalling of products can constrain the market for drug delivery systems market.

Laws and regulations that impose strict quality standards and compliance requirements, in addition to product recalls, might limit the market for medication delivery systems. Regulatory barriers can raise development costs and cause product introductions to be delayed, such as protracted approval procedures and changing safety requirements. Recalls brought on by safety issues or manufacturing flaws also undermine consumer trust, harm brand reputation, and result in monetary losses. For products to be safe and to comply with regulations, businesses need to make significant investments in quality control systems and follow rules.

Market Development

• September 2023- To provide the market with efficient and sustainable drug delivery solutions, West is extending its partnership with Corning®. With the introduction of Corning® ViridianTM Vials, West will be able to offer the healthcare sector a product that offers sustainability and performance thanks to this partnership with Corning Incorporated. Using 20% less glass material, ViridianTM Vials—an externally coated Type 1 borosilicate vial—allow for a 30% decrease in Cradle to Gate, Scope 3 emissions.
• January 2023- Nemera increased its production capacity in Poland. This Szczecin-based plant will greatly increase Nemera's manufacturing capacity and provide patients with more options for medicine delivery devices.

Market Segmentation

• By Delivery system
  • Intra Uterine Implants
  • Pro-drug Implants
  • Polymeric Drug Delivery
  • Targeted Drug Delivery
• By Route of Administration
  • Oral
  • Injectable
  • Inhalation
  • Transdermal
  • Ocular
  • Nasal
  • Topical
• By Application
  • Infectious Disease
  • Oncology
  • Ophthalmology
  • Urology
  • Diabetes
  • CNS
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. DRUG DELIVERY SYSTEM MARKET BY DELIVERY SYSTEM

5.1. Introduction

5.2. Intra Uterine Implants

5.2.1. Market Trends and Opportunities

5.2.2. Growth Prospects

5.3. Pro-drug Implants

5.3.1. Market Trends and Opportunities

5.3.2. Growth Prospects

5.4. Polymeric Drug Delivery

5.4.1. Market Trends and Opportunities

5.4.2. Growth Prospects

5.5. Targeted Drug Delivery

5.5.1. Market Trends and Opportunities

5.5.2. Growth Prospects

6. DRUG DELIVERY SYSTEM MARKET BY ROUTE OF ADMINISTRATION

6.1. Introduction

6.2. Oral

6.2.1. Market Trends and Opportunities

6.2.2. Growth Prospects

6.3. Injectable 

6.3.1. Market Trends and Opportunities

6.3.2. Growth Prospects

6.4. Inhalation

6.4.1. Market Trends and Opportunities

6.4.2. Growth Prospects

6.5. Transdermal

6.5.1. Market Trends and Opportunities

6.5.2. Growth Prospects

6.6. Ocular

6.6.1. Market Trends and Opportunities

6.6.2. Growth Prospects

6.7. Nasal

6.7.1. Market Trends and Opportunities

6.7.2. Growth Prospects

6.8. Topical

6.8.1. Market Trends and Opportunities

6.8.2. Growth Prospects

7. DRUG DELIVERY SYSTEM MARKET BY APPLICATION  

7.1. Introduction

7.2. Infectious Disease

7.2.1. Market Trends and Opportunities

7.2.2. Growth Prospects

7.3. Oncology

7.3.1. Market Trends and Opportunities

7.3.2. Growth Prospects

7.4. Ophthalmology

7.4.1. Market Trends and Opportunities

7.4.2. Growth Prospects

7.5. Urology

7.5.1. Market Trends and Opportunities

7.5.2. Growth Prospects

7.6. Diabetes

7.6.1. Market Trends and Opportunities

7.6.2. Growth Prospects

7.7. CNS

7.7.1. Market Trends and Opportunities

7.7.2. Growth Prospects

7.8. Others

7.8.1. Market Trends and Opportunities

7.8.2. Growth Prospects

8. DRUG DELIVERY SYSTEM MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Delivery System

8.2.2. By Route of Administration

8.2.3. By Application

8.2.4. By Country

8.2.4.1. United States

8.2.4.1.1. Market Trends and Opportunities

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Trends and Opportunities

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Trends and Opportunities

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Delivery System

8.3.2. By Route of Administration

8.3.3. By Application

8.3.4. By Country 

8.3.4.1. Brazil

8.3.4.1.1. Market Trends and Opportunities

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Trends and Opportunities

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Trends and Opportunities

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Delivery System

8.4.2. By Route of Administration

8.4.3. By Application

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.1.1. Market Trends and Opportunities

8.4.4.1.2. Growth Prospects

8.4.4.2. Germany

8.4.4.2.1. Market Trends and Opportunities

8.4.4.2.2. Growth Prospects

8.4.4.3. France

8.4.4.3.1. Market Trends and Opportunities

8.4.4.3.2. Growth Prospects

8.4.4.4. Italy

8.4.4.4.1. Market Trends and Opportunities

8.4.4.4.2. Growth Prospects

8.4.4.5. Spain

8.4.4.5.1. Market Trends and Opportunities

8.4.4.5.2. Growth Prospects

8.4.4.6. Others

8.4.4.6.1. Market Trends and Opportunities

8.4.4.6.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Delivery System

8.5.2. By Route of Administration

8.5.3. By Application

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Trends and Opportunities

8.5.4.1.2. Growth Prospects

8.5.4.2. UAE

8.5.4.2.1. Market Trends and Opportunities

8.5.4.2.2. Growth Prospects

8.5.4.3. Others

8.5.4.3.1. Market Trends and Opportunities

8.5.4.3.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Delivery System

8.6.2. By Route of Administration

8.6.3. By Application

8.6.4. By Country

8.6.4.1. Japan

8.6.4.1.1. Market Trends and Opportunities

8.6.4.1.2. Growth Prospects

8.6.4.2. China

8.6.4.2.1. Market Trends and Opportunities

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Trends and Opportunities

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Trends and Opportunities

8.6.4.4.2. Growth Prospects

8.6.4.5. Taiwan

8.6.4.5.1. Market Trends and Opportunities

8.6.4.5.2. Growth Prospects

8.6.4.6. Thailand

8.6.4.6.1. Market Trends and Opportunities

8.6.4.6.2. Growth Prospects

8.6.4.7. Indonesia

8.6.4.7.1. Market Trends and Opportunities

8.6.4.7.2. Growth Prospects

8.6.4.8. Others

8.6.4.8.1. Market Trends and Opportunities

8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Gerresheimer AG 

10.2. BD (Becton, Dickinson and Company) 

10.3. Kindeva Drug Delivery 

10.4. Baxter 

10.5. West Pharmaceutical Services Inc. 

10.6. Ypsomed 

10.7. Medtronic 

10.8. Nemara 

10.9. E3D Elcam Drug Delivery Devices 

Gerresheimer AG 

BD (Becton, Dickinson, and Company) 

Kindeva Drug Delivery 

Baxter 

West Pharmaceutical Services Inc. 

Ypsomed 

Medtronic 

Nemara 

E3D Elcam Drug Delivery Devices